Statement of Changes in Beneficial Ownership (4)
August 11 2021 - 5:16PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
RAKIN KEVIN |
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC.
[
ORMP
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
36 CHURCH LANE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/9/2021 |
(Street)
WESTPORT,, CT 06880
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 8/9/2021 | | M | | 5697 | A | $6.23 | 20758 | D | |
Common Stock | 8/9/2021 | | F | | 1683 (1) | D | $21.09 | 19075 | D | |
Common Stock | 8/9/2021 | | M | | 6666 | A | $4.80 | 25741 | D | |
Common Stock | 8/9/2021 | | F | | 1517 (2) | D | $21.09 | 24224 | D | |
Common Stock | 8/9/2021 | | M | | 10000 | A | $4.17 | 34224 | D | |
Common Stock | 8/9/2021 | | F | | 1977 (3) | D | $21.09 | 32247 | D | |
Common Stock | 8/9/2021 | | M | | 56773 | A | $7.77 | 89020 | D | |
Common Stock | 8/9/2021 | | F | | 20916 (4) | D | $21.09 | 68104 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $6.23 | 8/9/2021 | | M | | | 5697 | 2/9/2017 | 2/9/2027 | Common Stock | 5697 | $0 | 0 | D | |
Stock Option (right to buy) | $4.80 | 8/9/2021 | | M | | | 6666 | 12/31/2020 | 1/8/2030 | Common Stock | 6666 | $0 | 0 | D | |
Stock Option (right to buy) | $4.17 | 8/9/2021 | | M | | | 10000 | 12/31/2019 | 9/11/2029 | Common Stock | 10000 | $0 | 0 | D | |
Stock Option (right to buy) | $7.77 | 8/9/2021 | | M | | | 56773 | (5) | 6/30/2027 | Common Stock | 56773 | $0 | 0 | D | |
Explanation of Responses: |
(1) | Represents a cashless exercise of outstanding stock options to purchase 5,697 shares of common stock. The reporting person received 4,014 shares of common stock and surrendered 1,683 shares of common stock underlying the stock option in payment of the exercise price. |
(2) | Represents a cashless exercise of outstanding stock options to purchase 6,666 shares of common stock. The reporting person received 5,149 shares of common stock and surrendered 1,517 shares of common stock underlying the stock option in payment of the exercise price. |
(3) | Represents a cashless exercise of outstanding stock options to purchase 10,000 shares of common stock. The reporting person received 8,023 shares of common stock and surrendered 1,977 shares of common stock underlying the stock option in payment of the exercise price. |
(4) | Represents a cashless exercise of outstanding stock options to purchase 56,773 shares of common stock. The reporting person received 35,857 shares of common stock and surrendered 20,916 shares of common stock underlying the stock option in payment of the exercise price. |
(5) | The options vested as follows: 15,591 vested on December 31, 2017, 2018 and 2019 and additional 10,000 vested on December 31, 2020. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
RAKIN KEVIN 36 CHURCH LANE WESTPORT,, CT 06880 | X |
|
|
|
Signatures
|
/s/ Kevin Rakin | | 8/11/2021 |
**Signature of Reporting Person | Date |
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024